Abbott has launched the new Afinion 2 analyser in the US to allow diabetes management through haemoglobin A1c (HbA1c) and albumin to creatinine ratio (ACR) measurements.

The next generation Afinion test system has been designed as a rapid, multi-assay platform to provide optimised and simplified results that are accurate and actionable at point-of-care.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Afinion 2 delivers HbA1c and ACR measurements in three and five minutes, respectively, which enable healthcare professionals to make rapid yet accurate medical decisions.

“The test system can be used at physician offices, clinics, community health centres, hospitals and long-term care facilities, among other out-patient environments.”

This fast delivery of results also provides the physicians with more time to counsel patients in one office visit.

Furthermore, the platform facilitates all-in-one connectivity to laboratory and hospital information systems (LIS/HIS), while offering a quieter experience for both clinicians and patients.

The test system can be used at physician offices, clinics, community health centres, hospitals and long-term care facilities, among other out-patient environments.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Abbott Cardiometabolic and Informatics divisional vice-president Elizabeth Balthrop said: “By delivering rapid HbA1c and ACR test results, the Afinion 2 analyser does more than streamline care; its life-changing technology helps people living with diabetes get the most out of their healthcare visits.

“Within a single visit, patients can obtain real-time feedback and insights on their condition, have an informed discussion with their provider and leave with a defined care plan.”

HbA1c is used to identify average glycaemic control or blood sugar and determine the quality of diabetes management of a patient, while ACR is a kidney complications biomarker that indicates poor management of the condition.

By offering measurements for both these markers, the new system is expected to improve outcomes and minimise visits for patients.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact